Hims & Hers Health, Inc. (NYSE:HIMS) surged 14.4% last week ahead of its Q2 earnings announcement, with share prices rising from $50.38 to $57.65 on Friday. Zacks Research gave HIMS a “strong buy” rating, anticipating a 177.8% increase in earnings per share by 2025. The company acquired ZAVA, expanding its reach to over 1.3 million active customers in Europe. Integration of ZAVA’s technology is expected to enhance HIMS’ digital healthcare services across key European markets. While HIMS shows promise, other AI stocks may offer higher returns with limited downside risk. If seeking an affordable AI stock with potential benefits from Trump tariffs, consider our free report on the best short-term AI stock.

Read more at Yahoo Finance: Hims & Hers (HIMS) Jumps 14.4% W/W Ahead of Q2 Earnings